Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04227704 · ClinicalTrials.gov registry record · Phase 3
Ketamine to Prevent PPD After Cesarean
A Phase 3 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 3
- Development phase
- 25
- Enrollment target
NCT04227704 is a Phase 3 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 25 participants.
The verdict
NCT04227704, a Phase 3 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 25 participants
- Enrollment target
Study Summary
The investigators plan to randomise participants to receive ketamine or placebo control subcutaneously or by 40-minute intravenous infusions and will follow them up for 42 days to assess the incidence of postpartum depression. This feasibility pilot study is designed to explore the adequacy of the study procedures and tolerability of the interventions.
Interventions
- DRUG Control
- DRUG Ketamine 50 MG/ML
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-11-12 |
| Est. Completion | 2021-08-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04227704
The ClinicalTrials.gov registry entry for NCT04227704 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.
NCT04227704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04227704 about?
NCT04227704 is a clinical study titled "Ketamine to Prevent PPD After Cesarean". The investigators plan to randomise participants to receive ketamine or placebo control subcutaneously or by 40-minute intravenous infusions and will follow them up for 42 days to assess the incidence of postpartum depression. This feasibility pilot study is designed to explore the adequacy of the s...
What is the current status of trial NCT04227704?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 25 participants. The study started on 2020-11-12. Estimated completion is 2021-08-09.
What interventions are being tested in trial NCT04227704?
The interventions under investigation include: Control (DRUG), Ketamine 50 MG/ML (DRUG).
Who is sponsoring clinical trial NCT04227704?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.